Carregant...
Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
This 6-week, double-blind, placebo-controlled, proof-of-concept study evaluated the efficacy, safety, and tolerability of low-dose (1.5–4.5 mg/day) and high-dose (6–12 mg/day) cariprazine in patients with acute exacerbation of schizophrenia (NCT00404573). The primary efficacy measure was change in t...
Guardat en:
| Publicat a: | Int Clin Psychopharmacol |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Lippincott Williams And Wilkins
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4736298/ https://ncbi.nlm.nih.gov/pubmed/26655732 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/YIC.0000000000000110 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|